checkAd

     287  0 Kommentare Vaxart’s Oral COVID-19 Vaccine Candidate Induces Potent Systemic and Mucosal Immune Responses in Preclinical Studies - Seite 3

    References and Links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Vaxart is not responsible for the contents of third-party websites.

    Contacts:  
    Media Relations Investor Relations
    Gloria Gasaatura
    LifeSci Communications
    Tel: (646) 970-4688
    ggasaatura@lifescicomms.com      		Joyce Allaire
    LifeSci Advisors, LLC
    617 435 6602
    jallaire@lifesciadvisors.com

    Lesen Sie auch


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Vaxart’s Oral COVID-19 Vaccine Candidate Induces Potent Systemic and Mucosal Immune Responses in Preclinical Studies - Seite 3 Triggering mucosal immunity may be crucial for effective protection against SARS-CoV-2 infection and transmission Vaxart’s oral tablet vaccine can overcome major challenges of injectable vaccines SOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 …